JP2024517318A - アザシチジンと組み合わせて骨髄異形成症候群の処置に使用されるベネトクラクス投与レジメン - Google Patents

アザシチジンと組み合わせて骨髄異形成症候群の処置に使用されるベネトクラクス投与レジメン Download PDF

Info

Publication number
JP2024517318A
JP2024517318A JP2023569885A JP2023569885A JP2024517318A JP 2024517318 A JP2024517318 A JP 2024517318A JP 2023569885 A JP2023569885 A JP 2023569885A JP 2023569885 A JP2023569885 A JP 2023569885A JP 2024517318 A JP2024517318 A JP 2024517318A
Authority
JP
Japan
Prior art keywords
count
nadir
baseline
blood cell
white blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023569885A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517318A5 (https=
Inventor
ヘイスリップ，ジョン
カイ，スティーブ・エイチ
エインズワース，ウィリアム・ビー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of JP2024517318A publication Critical patent/JP2024517318A/ja
Publication of JP2024517318A5 publication Critical patent/JP2024517318A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Dermatology (AREA)
JP2023569885A 2021-05-11 2022-05-10 アザシチジンと組み合わせて骨髄異形成症候群の処置に使用されるベネトクラクス投与レジメン Pending JP2024517318A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163201749P 2021-05-11 2021-05-11
US63/201,749 2021-05-11
PCT/US2022/028429 WO2022240786A1 (en) 2021-05-11 2022-05-10 Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine

Publications (2)

Publication Number Publication Date
JP2024517318A true JP2024517318A (ja) 2024-04-19
JP2024517318A5 JP2024517318A5 (https=) 2025-05-16

Family

ID=84028499

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023569885A Pending JP2024517318A (ja) 2021-05-11 2022-05-10 アザシチジンと組み合わせて骨髄異形成症候群の処置に使用されるベネトクラクス投与レジメン

Country Status (11)

Country Link
US (1) US20220378811A1 (https=)
EP (1) EP4337183A4 (https=)
JP (1) JP2024517318A (https=)
KR (1) KR20240006659A (https=)
CN (1) CN117642161A (https=)
AU (1) AU2022273023A1 (https=)
BR (1) BR112023023677A2 (https=)
CA (1) CA3219760A1 (https=)
IL (1) IL308321A (https=)
MX (1) MX2023013364A (https=)
WO (1) WO2022240786A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10052346B2 (en) * 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
KR20220004669A (ko) * 2019-04-29 2022-01-11 이뮤노젠 아이엔씨 항-cd123 면역접합체를 포함하는 치료적 조합물
JP2022537551A (ja) * 2019-06-20 2022-08-26 セルジーン・クオンティセル・リサーチ・インコーポレイテッド ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン
WO2021037933A1 (en) * 2019-08-28 2021-03-04 Astrazeneca Ab Combination of azd2811 nanoparticles, 5-azacitidine and venetoclax for use in the treatment of cancer

Also Published As

Publication number Publication date
AU2022273023A1 (en) 2023-11-23
MX2023013364A (es) 2023-11-27
US20220378811A1 (en) 2022-12-01
EP4337183A4 (en) 2025-04-23
KR20240006659A (ko) 2024-01-15
WO2022240786A1 (en) 2022-11-17
EP4337183A1 (en) 2024-03-20
IL308321A (en) 2024-01-01
CA3219760A1 (en) 2022-11-17
CN117642161A (zh) 2024-03-01
BR112023023677A2 (pt) 2024-02-20

Similar Documents

Publication Publication Date Title
Gerhartz et al. Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas [see comments]
US20260103532A1 (en) Pharmaceutical compositions of humanized anti-cd40 antibodies and uses thereof
JP2024517935A (ja) Ｃｙｐ３ａ阻害剤及びアザシチジンと組み合わせて骨髄異形成症候群の処置に使用されるベネトクラクス投与レジメン
JP2023154026A (ja) 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法
JP2024517318A (ja) アザシチジンと組み合わせて骨髄異形成症候群の処置に使用されるベネトクラクス投与レジメン
US20240190971A1 (en) USE OF an anti-P-selectin antibody
Zhao et al. A first-in-class JAK/ROCK inhibitor, rovadicitinib, for glucocorticoid-refractory or-dependent chronic GVHD
TW202200202A (zh) 非耗竭性抗ｃｄ６單株抗體於治療細胞激素風暴之用途
TWI883004B (zh) 治療全身性硬化症之方法
Macaluso et al. JAK inhibition as a therapeutic strategy for inflammatory bowel disease
US20230338402A1 (en) Treatment regimen for cancer using immunomodulation
WO2025045766A1 (en) Compositions comprising humanized anti-cd40 antibodies and methods for treating rheumatoid arthritis using the same
HK40106739A (zh) 与阿扎胞苷联合用於治疗骨髓增生异常综合征的维奈托克给药方案
Rodríguez Management of the adverse effects of lenalidomide in multiple myeloma
WO2024155790A2 (en) Novel approach for treatment of cancer using immunomodulation
HK40106881A (zh) 与cyp3a抑制剂和阿扎胞苷联合治疗骨髓增生异常综合征的维奈托克给药方案
Ecsiova et al. Pulmonary damage in a patient with hairy cell leukemia-infectious involvement or hematological disease activity? Case report
RU2828013C1 (ru) Композиции антител к cd6 и способы лечения и снижения негативных последствий коронавируса, включая covid-19
Jovićević et al. Ocrelizumab associated late-onset neutropenia in the patient with multiple sclerosis: Case report and literature review
WO2025122961A1 (en) Methods for treating neutropenia
Musch et al. Randomized, double-blind, placebo-controlled, phase III study of
McDonnell et al. Review of immunosuppressive treatment in lung transplantation
HK40079147A (en) Use of multi-target protein kinase inhibitor
Scheinberg et al. CLINICAL RESEARCH PROJECT
Schmitt et al. CLINICAL NEPHROLOGY-EPIDEMIOLOGY-CLINICAL TRIALS Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): An open study in 15 patients.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250508

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250508

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260421

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260423